Novo Nordisk CEO Mike Doustdar said on Monday that as many as 1.5 million people in the United States may be using compounded versions of GLP-1 weight-loss drugs, highlighting how cheaper and unapproved alternatives have gained traction in the fast-growing obesity treatment market.
13 Jan 2026-15:46
13 Jan 2026-15:46
